Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there. Did your doctor somehow miss the recovery protocol that Pedro Bach-y-Rita used to recover fully back in 1958 with only a partial brain?

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, April 13, 2011

Vascular endothelial growth factor (VEGF

more details to keep you confused, I am.
definition:
Vascular endothelial growth factor (VEGF): A substance made by cells that stimulates new blood vessel formation, a mitogen for vascular endothelial (vessel lining) cells.
VEGF is a polypeptide structurally related to platelet-derived growth factor (PDGF). The gene for VEGF is on chromosome 6p12.


Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo

http://www.pnas.org/content/99/18/11946.full

Abstract

Vascular endothelial growth factor (VEGF) is an angiogenic protein with neurotrophic and neuroprotective effects. Because VEGF promotes the proliferation of vascular endothelial cells, we examined the possibility that it also stimulates the proliferation of neuronal precursors in murine cerebral cortical cultures and in adult rat brain in vivo. VEGF (>10 ng/ml) stimulated 5-bromo-2′-deoxyuridine (BrdUrd) incorporation into cells that expressed immature neuronal marker proteins and increased cell number in cultures by 20–30%. Cultured cells labeled by BrdUrd expressed VEGFR2/Flk-1, but not VEGFR1/Flt-1 receptors, and the effect of VEGF was blocked by the VEGFR2/Flk-1 receptor tyrosine kinase inhibitor SU1498. Intracerebroventricular administration of VEGF into rat brain increased BrdUrd labeling of cells in the subventricular zone (SVZ) and the subgranular zone (SGZ) of the hippocampal dentate gyrus (DG), where VEGFR2/Flk-1 was colocalized with the immature neuronal marker, doublecortin (Dcx). The increase in BrdUrd labeling after the administration of VEGF was caused by an increase in cell proliferation, rather than a decrease in cell death, because VEGF did not reduce caspase-3 cleavage in SVZ or SGZ. Cells labeled with BrdUrd after VEGF treatment in vivo include immature and mature neurons, astroglia, and endothelial cells. These findings implicate the angiogenesis factor VEGF in neurogenesis as well.
Vascular endothelial growth factor (VEGF) is a hypoxia-inducible secreted protein that interacts with receptor tyrosine kinases on endothelial cells to promote angiogenesis. Recent evidence indicates that VEGF can also act directly on neurons to produce neurotrophic and neuroprotective effects. For example, VEGF stimulates axonal outgrowth and improves the survival of cultured superior cervical and dorsal root ganglion neurons (1, 2), enhances the survival of mesencephalic neurons in organotypic explant cultures (3), protects HN33 (mouse hippocampal neuron × neuroblastoma) cells from death induced by serum withdrawal (4), reduces hypoxic death of HN33 cells and cultured cerebral cortical neurons (5), and protects cultured hippocampal neurons from glutamate toxicity (6). Conversely, inhibition of VEGF signaling leads to apoptosis in cortical neuron cultures (7), and deletion of the hypoxia-response element from the VEGF promoter causes motor-neuron degeneration in mice (8), perhaps because of loss of a direct neurotrophic effect of VEGF.
Neurogenesis, the process through which precursor cells differentiate toward a mature neuronal phenotype, persists in discrete regions of the adult brain, including the rostral subventricular zone (SVZ) (9, 10) and the subgranular zone (SGZ) of the hippocampal dentate gyrus (DG) (11). Comparatively little is known regarding the possible role of VEGF in adult neurogenesis, although other growth factors, including epidermal growth factor (EGF) (12), fibroblast growth factor-2 (FGF-2) (13), brain-derived neurotrophic factor (BDNF) (14), and erythropoietin (15), have been implicated. In addition, the VEGF receptor Flk-1 is expressed in neural progenitor cells of the mouse retina (16), and its activation stimulates their differentiation into amacrine neurons and photoreceptor cells (17). Finally, neurogenesis in the adult SGZ appears to occur in intimate association with angiogenesis, suggesting that common factors, such as VEGF, might be involved in both processes (18).
To investigate the possibility that VEGF is a neurogenic as well as an angiogenic factor, we examined its effects in in vitro and in vivo models of neurogenesis, by using the cell-proliferation marker 5-bromodeoxyuridine (BrdUrd). The in vitro model employs primary cultures of embryonic rat cortical neurons, and has been used to identify growth factors involved in hypoxia-induced neurogenesis, including heparin-binding EGF (19). The in vivo model involves intracerebroventricular (i.c.v.) administration of growth factors in the adult rat, and has been used to study the induction of neurogenesis in the brain in vivo by factors such as EGF, FGF-2, and BDNF (20–22).

I would prefer that I not have to go to medical school and do all this on my own. There has to be enough smart people out there who care to completely change stroke rehab (rehab protocols, OT, PT and PMR doctor schooling). I've given up on the stroke associations.

Digital Atlas of the Human Brain

See the brain here: www.brain-map.org Not sure if this is really any use to us survivors except to question our doctors. Although maybe we could figure out the epigenics of neuron regeneration.
Scientists funded by Microsoft Corp. co-founder Paul Allen unveiled a $55 million computerized atlas of the human brain Tuesday, offering the first interactive research guide to the anatomy and genes that animate the mind.
A project of the Seattle-based Allen Institute for Brain Science, the online atlas offers researchers a powerful new tool to understand where and how genes are at work in the brain. That could help them find new clues to conditions rooted in the brain, such as Alzheimer's disease, autism and mental-health disorders like depression.
"Until now, a definitive map of the human brain at this level of detail simply hasn't existed," said Allan Jones, the nonprofit institute's chief executive. "For the first time, we have generated a comprehensive map of the brain that includes the underlying biochemistry."
Allen Institute for Brain Science
A thin section of human brain tissue was used to help compile the Allen Insitute's brain atlas in Seattle.
Scientists have unveiled a computerized atlas of the human brain that charts the underlying biochemistry of the mind. WSJ's Robert Lee Hotz talks with Kelsey Hubbard about how it was created and how researchers hope to use it.
The institute is making the atlas freely available at www.brain-map.org as a resource for scientists studying brain diseases, along with a set of computational tools to help them analyze the data for clues to conditions such as Alzheimer's disease, autism and mental-health disorders like depression.
Advances in the ability to probe the human brain have driven a renaissance in neuroscience in recent decades. The new online atlas is considered significant because it combines several reliable imaging techniques into one three-dimensional interactive archive that accurately maps overall anatomy, nerve structure, cell features and a comprehensive read-out of gene activity.
"The Allen atlas tells you where a gene is turned on in the brain and that's why it is important," said neurologist Jeffrey L. Noebels, who studies epilepsy at the Baylor College of Medicine in Houston.
Until now, researchers have been hard-pressed to link symptoms of the diseases they study to the biochemistry of genes that might be responsible for them.
"The location of where these genes are active is at the very center of understanding how brain diseases work," Dr. Noebels said.
The atlas has cataloged 1,000 anatomical landmarks in each of two normal adult brains, donated for research, and then linked those tissues to thousands of genes that must act in complex combinations for normal neural development and function. The atlas encompasses more than 100 million data points measuring how strongly or weakly different genes acted at each landmark.
As they assembled the brain images and genetic data, the researchers were surprised to discover that by this neural measure, any two people are 94% alike. Moreover, they found that more than 80% of all known human genes are actively at work in the brain.
This first edition of the atlas took four years to compile and, in its preliminary drafts, has already become a research tool for 4,000 scientists who have adopted it to probe brain biology. It builds on computer techniques that the Allen Institute developed during the creation of an interactive atlas of the mouse brain, which it released in 2006.
Yet the human brain atlas is far from finished. So far, the online archive is exclusively male. The researchers expect to add eight more brains to the archive by the end of next year, to better account for variations between people. The researchers said that, when completed, the online archive will include one or more female brains.
In the meantime, "We feel confident that we are giving a good average picture of the human brain to the people who are mining this data," said Dr. Jones.
Write to Robert Lee Hotz at sciencejournal@wsj.com

Froomsplint and hand anti-spasticity

It was depressing that a caregiver had to do this rather than an OT who may see dozens of these every year. I do wonder how the Saebo-stretch would compare.
pictures here: http://www.abledata.com/abledata.cfm?pageid=19327&top=185093&deep=2&trail=11763,11824

article here:
http://www.symptomsbo.com/a-new-area-of-stroke-rehabilitation-froomsplint-to-provide-independence-for-the-victim-and-caregiver-4561.html
Gardena, CA (PRWEB) October 31, 2005
In 2003 while providing care for his mother after she survived a major stroke, Keith Froom, third generation inventor with 20 years of experience in research, design and manufacturing, designed the anti-spasticity Froomsplint® out of frustration with available splints and stroke therapy technology. After having used the Froomsplint®, his mother has had remarkable recovery that includes restoration of movement in the previously paralyzed side, the ability to perform all tasks previously enjoyed and a return to full-time office administration (typing, using computers, etc.). Carol Froom regained her driving privileges and is creating beautiful hand crafted greeting cards in her spare time.

When neurological paralysis occurs, the muscles involved don’t work and quickly begin to atrophy, which causes a shortening of muscles and thereby the “clawing” one often sees on stroke survivors. The available splints, Keith discovered, were bent to accommodate that clawing rather than correct it. In fact, he discovered that 60-80% of the physical therapy sessions were spent massaging and stretching hand and arm muscles; hence, only 10 – 15 minutes were available for rehabilitation.

In addition, without use of one body side, his mother and other rehab patients he observed were unable to perform the simplest of tasks like wiping on the toilet, washing in the shower and getting dressed. It became obvious why so much of stroke recovery is overcoming depression. So Keith got busy.

The Froomsplint®

The Froomsplint® is machined out of high quality plastic and has straps that attach to the hand it is available in small, medium and large sizes. It is reversible for right or left hand in a rigid model or an adjustable thumb model. Most importantly, the Froomsplint® hand orthosis can be applied or removed easily by patients, therapists or caregivers, minimizing the need for expensive tape; it is available by special order in smaller sizes for children. . The Froomsplint also has patented accessories that attach to walkers, wheelchairs and restroom fixtures. Keith Froom has also patented a line of exercise devices for rehabilitation.

Benefits of the Froomsplint®

Froomsplint is compact, comfortable and adjustable, easily used by the patient or caregiver. It expands weight-bearing rehabilitation from a supervised regimen to simple home-based therapy, creating a whole new area of stroke rehabilitation.
Allows for an extended weight-bearing surface, which in turn facilitates motor recovery, and aids patients and caregivers in performing stretching, strengthening and stabilization exercises. .
Helps maintain a weight-bearing surface for a recovering limb, so that dropping, holding and moving the upper body trunk, in relation to the distal limbs, is possible.
R.K. Froom & Co. Inc.

R.K. Froom & Co. Inc. was established in 2003 specifically to research and develop a line of medical equipment to aid the medical community in the home healthcare and rehabilitation field.

Businesses interested in manufacturing, licensing and distributing R.K. Froom & Co. Inc.’s integrated line of over fifteen stroke and rehabilitation devices for wheelchairs, walkers and home care are invited to contact us. The Froomsplint and its related devices were awarded patent # 6,949,077 by the United States Patent and Trademark Office on September 27th, 2005.

My OT was great at making splints but with a better selection of manufacturable ones, I would have been able to get therapy during that time rather than being the model for the splint. And with hundreds of thousands of stroke survivors that means that many more hours of therapy that could be provided. The therapy schools could change their curricula to de-emphasize splint creation and work on learning more therapies for hand recovery.
Oh well, more tilting at windmills. PTs and PMR docs to come yet.

vibrating legs

Sometimes known as nervous energy. I can bounce my good/right leg up and down.  My wife dislikes this at the kitchen table. I have been working on doing this with my bad/left leg and can now do this fairly regularily. I think once it gets going there is no longer any brain control because I think it is driven by the spine. So it may not be useful for any type of rehab, but I like it because its the only form of fast twitch muscles I can fire right now.  I even have an AFO on.
Remember this is only to be tried with your doctors supervision.

cpsp - central post-stroke pain

I didn't have this but some people I know did
Some research;
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T0K-4864XWP-6R&_user=10&_coverDate=01%2F31%2F1989&_rdoc=1&_fmt=high&_orig=gateway&_origin=gateway&_sort=d&_docanchor=&view=c&_searchStrId=1716204310&_rerunOrigin=google&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=361c1f1cf672fdf23d67e993befa2779&searchtype=a

Abstract

A double-blind, 3-phase, cross-over, placebo-controlled trial of the pain-relieving effect of amitriptyline and carbamazepine was carried out in 15 patients with central post-stroke pain (CPSP) but without signs of depression. Treatment was given, in randomized order, for periods of 4 weeks, separated by 1 week wash-out. The final doses were 75 and 800 mg/day, respectively, for amitriptyline and carbamazepine. The treatment effects were assessed by daily ratings of pain intensity on a 10-step verbal scale and at the end of each treatment period by a global rating of the analgesic effect on a 5-step verbal scale. For the assessment of depression the Comprehensive Psychopathological Rating Scale (CPRS) was used.
Amitriptyline produced a statistically significant reduction of pain when compared to placebo. According to the global rating, 10 of the 15 patients were responders to this drug. The effect could already be noticed during the second treatment week and it appeared to be correlated to the plasma concentration, since the median total ami- and nortriptyline concentrations were 497 and 247 nmol/1, respectively, for responders and non-responders. The early onset, together with the fact that the patients were not depressed, nor did they obtain reduced scores on ratings of depressive symptoms and signs, provides strong support for the conclusion that the pain relief was not caused by an antidepressive effect.
Five of the 14 patients treated with carbamazepine reported some pain relief, but the effect did not reach statistical significance when compared to placebo. No correlation was found between effect and plasma concentration.
In general, the patients tolerated the planned final dose of amitriptyline well. No final dose reduction was necessary. Carbamazepine caused more side effects and the final dose had to be reduced in 4 patients. However, only 1 patient had to be taken off medication, on day 25, due to drug interaction.
Keywords: Central post-stroke pain; Controlled trial; Amitriptyline; Carbamazepine; Placebo

Or:


http://thejns.org/doi/abs/10.3171/jns.1998.89.4.0585

Object. The goal of this study was to identify the neurological characteristics of patients with poststroke pain who show a favorable response to motor cortex (MC) stimulation used to control their pain.
Methods. The neurological characteristics of 31 patients treated by MC stimulation were analyzed. In 15 patients (48%), excellent or good pain control (pain reduction > 60%) was achieved for follow-up periods of more than 2 years by using MC stimulation at intensities below the threshold for muscle contraction. Satisfactory pain control was achieved in 13 (73%) of 18 patients in whom motor weakness in the painful area was virtually absent or mild, but in only two (15%) of the 13 patients who demonstrated moderate or severe weakness in the painful area (p < 0.01). Muscle contraction was inducible in the painful area in 20 patients when stimulated at a higher intensity. No such muscle response was inducible in the remaining 11 patients, no matter how extensively the authors attempted to determine appropriate stimulation sites. Satisfactory pain control was achieved in 14 (70%) of the 20 patients in whom muscle contraction was inducible, but in only one (9%) of the 11 patients in whom muscle contraction was not inducible (p < 0.01). No significant relationship was observed between pain control and various sensory symptoms, including the presence of hypesthesia, spontaneous dysesthesia, hyperpathia, and allodynia, or the disappearance of the N20 component of the median nerve—evoked somatosensory scalp potential. No significant relationship existed between the effect of MC stimulation on the pain and stimulation-induced phenomena, including paresthesia, improvement in motor performance, and attenuation of involuntary movements.
Conclusions. These findings suggest that the pain control afforded by MC stimulation requires neuronal circuits that are maintained by the presence of intact corticospinal tract neurons originating from the MC. Preoperative evaluation of motor weakness of the painful area appears to be useful for predicting a favorable response to MC stimulation in the control of poststroke pain.
Key Words • central pain • motor cortex • pain • brain stimulation • stroke • thalamic pain


This site has lots of good information:
http://www.painclinic.org/nervepain-centralpoststrokepain.htm

exercises for stroke rehab

I know survivors are constantly on the lookout for exercises. I really don't think specific exercises are the magic pill and I talk about that here: http://oc1dean.blogspot.com/2010/11/what-therapy-exercise-worked-best-for.html
But if you are on your own or maybe you want to bring up some of your own to your therapist.
try
http://www.exrx.net/Lists/Directory.html
http://www.physio4all.webs.com/
http://www.physiotherapyexercises.com/
http://www.exerciseprescriber.com/ This one does require a subscription but by selecting muscle groups you can see the initial starting position for the exercise without paying for the video.
And thanks to Amy for these.
http://www.smyrnahighsoccer.com/exercises/QuadBodyWeightt.htm

Monday, April 11, 2011

Frogs and stroke rehab

I told you I can correlate anything to stroke rehab.
This came from Maree of Australia and I had to share
Two Frogs
By: Author Unknown
A number of frogs were traveling through the woods. Two of
them fell into a deep pit. All the other frogs gathered
around the pit. When they saw how deep the pit was, they
told the two frogs that they were as good as dead.
The two frogs ignored the comments and tried to jump up out
of the pit with all of their might. The other frogs kept
telling them to stop, that they were as good as dead.
Finally, one of the frogs took heed to what the other frogs
were saying and gave up. He fell down and died.
The other frog continued to jump as hard as he could.
Once again, the crowd of frogs yelled at him to stop the
pain and just die. He jumped even harder and finally made
it out.
When he got out, the other frogs said, "Did you not hear
us?" The frog explained to them that he was deaf. He
thought they were encouraging him the entire time.
This story teaches two lessons:
1. There is the power of life and death in the tongue. An
encouraging word to someone who is down can lift them up
and help them make it through the day.
2. A destructive word to someone who is down can be the
push over the edge. Be careful of what you say. Speak
life to those who cross your path. Anyone can speak
words that can rob another of the spirit to push forward
in difficult times. "Acceptance" is a destructive word.
This matches my blog on being a 'bad patient'.
http://oc1dean.blogspot.com/2010/10/you-should-be-bad-patient.html
Now if we could get our therapists and doctors to help us out
of the pit rather than standing on the sidelines yelling, 'You're in denial'.

And another;
--------------------------------------------------------------------------------------------------------
We think too small, like the frog at the bottom of the well. He thinks the sky is only as big as the top of the well. If he surfaced, he would have an entirely different view.
Mao Tse-Tung

And another;
---------------------------------------------------------------------------------------------------------
The phrase itself is borrowed from two quotes from Mark Twain:
- “If you eat a frog first thing in the morning, the rest of your day will be wonderful.”
- “If you have to eat a frog, don’t look at it for too long.”
Not sure how to take these, but I think it is - tackle the large and distasteful things first.

And another;
----------------------------------------------------------------------------------------------------------
http://166.122.164.43/archive/2003/June/06-24-tara.htm
TWO WAYS TO BOIL A FROG
By Tarcisius Tara Kabutaulaka
I think it was Mark Twain, author of the American classics, The Adventures of Tom Sawyer and Huckleberry Finn, who said that there are two ways to boil a live frog. The first involves heating the water until it boils and then throwing in the frog. It is likely the frog will feel the heat and jump out. The second involves putting the frog in a pot of cold water and then slowly heating up the water until it boils. He asserts that the frog will not realize the slow increase in temperature. It will change its body temperature to balance with the surrounding environment. By the time the frog realizes the water is too hot, it would have been boiled to death.
Now this is a metaphor, I take it to mean - Ask for your worst diagnosis all at once so you can rail against it and jump into action, rather than just meekly listening to your doctor describe the therapies you will need to go thru and not understanding the effort involved.

Treating sleep disorder improves stroke recovery

This is one of those blindingly obvious items, if you aren't tired you can participate in therapy better. So how do you get this into a stroke rehab protocol?
http://www.canadafreepress.com/index.php/articles-health/35183
TORONTO, A new study shows that patients in stroke rehabilitation treated for their co-existing obstructive sleep apnea (OSA) recovered better from stroke than those whose OSA was not treated.
The study, published in the April edition of the journal Stroke, found “significant improvements” in functional and motor outcomes as well as mood of stroke rehabilitation patients who received continuous positive airway pressure (CPAP), a small mask placed over the patient’s nose during sleep that alleviates OSA.

“These new findings are important because functional and motor impairments are often the most disabling features of stroke, limiting people’s mobility and participation in daily activities,” says Dr. Clodagh Ryan, lead author of the Toronto Rehab study. Dr. Ryan is assistant director of Toronto Rehab’s Sleep Research Laboratory and an adjunct scientist.
“If stroke patients get greater improvement in motor and functional outcomes, such as the ability to walk, dress and bathe themselves without assistance, they are going to be more independent and will function better at home.”
Stroke is a leading cause of disability in Canada. Only 10 per cent of people who have a stroke recover completely. The rest are left with permanent or long-lasting disability. The impact for stroke survivors, and for their families, can be enormous.
OSA is a disorder that causes a person to stop breathing repeatedly during sleep because of recurrent collapse of the throat. About five to 10 per cent of otherwise healthy people are believed to have OSA?but as many as 70 per cent of stroke patients have the disorder. Stroke patients with OSA have greater functional impairment and higher death rates than stroke survivors without OSA.
The new study involved 44 inpatients in Toronto Rehab’s stroke rehabilitation service. All were diagnosed with OSA. Half of the patients were treated with CPAP, while the other half did not receive CPAP.
“The impact on patients’ mobility, which is the major problem for most of our stroke patients, was quite dramatic,” says study co-author Dr. Douglas Bradley, a Toronto Rehab senior investigator who heads the hospital’s Sleep Research Laboratory.
During the four-week trial, he says, patients treated with CPAP showed “a markedly greater improvement in walking distance within six minutes, a test used to determine walking ability, compared to those not treated for sleep apnea.”
Impaired motor function of the leg is a major limitation to stroke recoverybecause it limits functional independence, the authors note. CPAP usage “could improve functional independence and hasten return to community living.”
How CPAP treatment produced these benefits is not clear. It could be due to increased brain blood flow and oxygen delivery, which alleviates adverse cardiovascular effects of sleep apnea, and possibly through enhanced ‘neuroplasticity,’ the authors suggest. Notably, CPAP treatment had marginal, if any, effects on cognitive outcomes in the new study.
The new study builds on previous research by Dr. Bradley that showed OSA plays a role in inhibiting recovery from stroke. His earlier studies found that stroke patients who have OSA spend much longer in rehabilitation and do not recover as well physically compared to stroke patients without the sleep disorder.
“With this study, we’ve moved forward to actually treat obstructive sleep apnea in these patients, and the results are exciting,” says Dr. Bradley. “These findings have implications for people’s independence and quality of life, and for reducing the burden on caregivers and the healthcare system.”
Although the findings are encouraging, several study limitations, including the small sample size, make it difficult to know whether the results apply to the general stroke population, the authors say. Also, larger, longer-term trials are needed to determine whether such improvements persist over longer periods.

And I got the finger clipon that said I wasn't OSA, by the time my oxygen poor blood would get to my finger I would have had to quit breathing for several minutes and currently be dead. My less than stellar introduction to CPAP is here; http://oc1dean.blogspot.com/2010/09/stroke-fatigue.html

MyVoice helps with autism and stroke aphasia

This kind of gets into whether you want to be able to compensate for aphasia or recover. With this I talk about that here: http://oc1dean.blogspot.com/2010/10/compensation-vs-recovery.html

http://ca.news.yahoo.com/myvoice-helps-autism-stroke-20110406-092443-911.html
A new iPhone app that will help people with autism or who are recovering from strokes has been developed in Canada.
The creator and lead researcher at the University of Toronto, Alexander Levy, says MyVoice, which says words when the iPhone screen is tapped, is advanced for a couple of reasons.
First of all, it is location aware. This means, explains Levy, that the phone knows where you are. Words and phases that are put in ahead of time, will automatically pop up.
"So to give you a very Canadian example. The concept is that if you were to walk into a Tim Hortons, you automatically get words like Timbits and double-double so you can communicate quickly and easily."
Secondly, as Levy told CBC's Matt Galloway, the software is supported by a website where caregivers or the user can log on and add words.
The response has been overwhelming. Levy says he never thought it would be a product but was often asked when it would be available when he took the prototype to conferences to demonstrate.
People like it, he says, because it is small, easy to use and allows them to communicate more fluidly and to fit in socially.
It is available for free from the iPhone AppStore or by going to the website myvoiceaac.com. The company is developing an app for the Android market.
In four to six months more features will be available through a monthly subscription fee. Proceeds from these sales, says Levy, will go toward making better speech aids.

Sunday, April 10, 2011

stroke rehab at the microwave

I usually bring my lunch to work and microwave it. The timing is usually 2-3 minutes. While I am waiting I do left leg lifts, trying to have my knee touch the counter while keeping the lower leg hanging straight down. For the microwave that has cabinets below this is quite a bit easier because I can let my toe rub against the cabinet.  Due  to spasticity this is rather difficult.

Remember these dangerous exercises should not be tried without your doctors permission.

Stroke rehab at the coffee machine

And finally some useful therapies rather than all this high-faluting doctor and researcher stuff.
At work we have free coffee machines, they are about chest high and I usually visit them twice each morning to get the wake-up quota of caffiene. They grind their own beans for each cup so it takes about a minute to fill your mug. I take my left arm/hand and place it on the top of the machine in order to stretch out the bicep and pec muscles. Currently there is no way I can get the arm up there by itself. It stays there for maybe 2 minutes at a stretch, 2 fillups for my mug. I know this isn't much as far as massed practice is concerned and there definitely would be no research showing this to be useful for anything. But because we survivors are left completely on our own we have to come up with our own therapy protocols. Do not do something like this without your doctors ok.

Reciprocal Inhibition

Something that would be good for you to understand for a better idea of what your spasticity is.
http://www.physiobob.com/forum/neuro-physiotherapy/1040-neuro-inhibitory-facillatory-technique.html#post3785

Reciprocal inhibition is the term used to describe a muscle's automatic response to the contraction of its opposite. When the Muscle Control Center (MCC) requests a muscle to contract, that muscle is facilitated, and the opposite, or reciprocal, muscle is required to relax, or become inhibited. The smooth facilitation of the contracting muscle depends upon the smooth release of its functional opposite. Though this is how we tend to explain this we should note that the decerebrate posture is one of flexion or rigidity. Therefore a flaccid arm is really an arm with a lot of input from the brain to relax the flexor tendency. To move say the biceps to flex the elbow would therefore to reduce that dampening on the biceps, whilst perhaps at the same time maybe even increasing it's "relaxation" of the triceps (or not as I am not sure on the reseach here). This concept makes working with head injury and stroke most interesting in deed.

Reciprocal inhibition is a built-in, automatic neurological function, designed to provide for optimum joint function and longevity. It is a fundamental function in proper body movement.

When all the neurological connections between the MCC and muscle are clear, the muscle will be able to respond smoothly and easily to the MCC's signals to work or relax. If one muscle becomes permanently facilitated, as in a cramp, spasm, or chronic tension, the opposite becomes correspondingly inhibited. This disables normal joint function, and results in stress that can lead to deterioration of the muscle, tendon, and joint tissues. In this case, if the client has spasms in their biceps and you test the triceps, you will find it weak.


Another simple example:


To get an idea of reciprocal inhibition in action, hold a heavy book in one hand, palm up. With your other hand feel the front of your upper arm. It's contracted and hard. Then, feel the back of your upper arm. It's relaxed, and flaccid. Include this as a flexibility technique to improve your active and PNF stretching.

Thanks to the Physiobob PT forum.

powered AFOs

This is definitely something for your doctor and therapist to determine if this is for you. I could see some of the more affected persons being able to use this.

http://www.springerlink.com/content/e165641671qn7202/fulltext.pdf

http://scitation.aip.org/getabs/servlet/GetabsServlet?prog=normal&id=JMDOA4000002000003031004000001&idtype=cvips&gifs=yes&ref=no

http://www.gaitposture.com/article/S0966-6362(08)00258-0/abstract

Although the outriggers on these severely limit what you could wear and the climate it could be used in.

Mindfulness meditation improves connections in the brain

I know there is nothing specific about stroke rehab in this. But if we can strengthen brain connections we can apply this to stroke rehab. 

Mindfulness meditation improves connections in the brain



When I’m stressed, I listen to a 20-minute mindfulness meditation tape. It always helps me feel calmer and more relaxed. Many meditative practices can do this. But mindfulness meditation is getting a lot of attention because it seems to help with so many physical and psychological problems—like high blood pressure, chronic pain, psoriasis, sleep trouble, anxiety, and depression. It’s also been shown to boost immune function and stop binge eating. No one knows for sure what’s behind these benefits, but physical changes in the brain probably play a role.
Mindfulness meditation is a mental discipline. You start by focusing your attention on your breath, a sensation in the body, or a chosen word or phrase. You note the thoughts, emotions, and background sounds that arise from moment to moment, observing them without analyzing them or making judgments about what’s going on around you. If you drift into thoughts about the past or concerns about the future, you bring your attention back to the present, for example, by refocusing on your breathing. It takes practice.
A new study, published in the May 2011 issue of Neuroimage, suggests that one effect of all this focusing and refocusing is increased brain connectivity. Researchers at the University of California-Los Angeles compared the brain activity of volunteers who had finished eight weeks of mindfulness-based stress reduction training with that of volunteers who did not do such training. Functional MRI scans showed stronger connections in several regions of the meditators’ brains—especially those associated with attention and auditory and visual processing. Unfortunately, the study didn’t scan the volunteers’ brains before mindfulness training, so no one can say for sure that mindfulness training was responsible for the differences.
At Massachusetts General Hospital, researchers used MRI scans to document before and after changes in the brain’s gray matter—the “processing” neurons—associated with mindfulness meditation. The density of gray matter increased in regions governing such distinctly different activities as memory, self-awareness, and compassion, and decreased in the amygdala—the part of the brain associated with fear and stress. We covered this intriguing research in the April issue of Harvard Women’s Health Watch.
At the moment, scientists can only speculate about the relationship between these brain changes and the health benefits associated with mindfulness meditation. But the research adds to growing evidence that meditative practices can alter the body at a fundamental level—even, it turns out, at the level of our genes. Meditation elicits the “relaxation response,” a state of deep relaxation first described more than 35 years ago by mind-body pioneer Dr. Herbert Benson, currently emeritus director of the Benson-Henry Institute of Mind-Body Medicine at Massachusetts General Hospital. Since then, Benson and his colleagues at Massachusetts General Hospital and Beth Israel Deaconess Medical Center have discovered that relaxation techniques (including meditation and yoga) turn certain sets of genes on and off in people who practice them regularly. Benson, who is the medical editor of Stress Management: Approaches for preventing and reducing stress (a Special Health Report from Harvard Health Publications, which also publishes Harvard Women’s Health Watch), says these genes are involved with controlling “how the body handles free radicals, inflammation processes, and cell death.” You can read about the gene research here.


So besides our physical exercises we need mental ones too. No rest for the weary. Ask your doctor if this would help.

A faster, better, cheaper clinical trial

Getting this done could mean that practices at hospitals could produce clinical trials and we would have the start of case studies.
Read this book to help you design experiments;
The design of experiments in neuroscience by Mary Harrington
http://scopeblog.stanford.edu/archives/2011/04/a-faster-better.html
It's still early days for electronic medical record systems, but a study published in Clinical Trials today shows how the VA Boston Healthcare System is using them to zero in on what treatments work best and get them to patients quicker. It's a really smart, less costly way to do clinical trials - it guides doctors to switch to the best treatment even before the trial is completed.
Stanford biostatistician Philip Lavori, PhD, the study's senior author, explains in an Inside Stanford Medicine article I co-wrote with Kris Newby:
Our idea is that if systems of care like the VA can integrate implementation of research results directly into care, we will keep the decision-making where it belongs. It brings medical decision-making back down to expert physicians and their patients, and out of the political realm.
The catch is this kind of trial is feasible only when a large group of physicians are all using a common electronic medical record system. Lavori told me that only two institutions are in a position to do this kind of study today: the VA and Kaiser.

We somehow have to change medical research so we can produce it faster. We could follow The Knife Man; http://oc1dean.blogspot.com/2011/03/surgery-transformation-into-scientific.html

Blood clot picture

Beautiful in a sinister way. From Credit: Yuri Veklich and John W. Weisel, University of Pennsylvania School of Medicine
here: http://www.uphs.upenn.edu/news/News_Releases/jun05/clotfiber_photo.htm
A colorized scanning electron microscope image of a whole blood clot. The fibrin fibers are blue, platelet aggregates purple, and red blood cells red.

Federal Research Center Will Help Develop Medicines

And this means another set of letters to write. If you've read most of my earlier posts there are at least a dozen possibilities for acute stroke rehab, either preventing cell death or repairing cells.

http://www.nytimes.com/2011/01/23/health/policy/23drug.html?_r=1&scp=1&sq=nih&st=cse
The Obama administration has become so concerned about the slowing pace of new drugs coming out of the pharmaceutical industry that officials have decided to start a billion-dollar government drug development center to help create medicines.
Jennifer S. Altman for The New York Times
Creating a drug development center is a signature effort of Dr. Francis S. Collins, director of the National Institutes of Health.

Readers' Comments

Readers shared their thoughts on this article.
The new effort comes as many large drug makers, unable to find enough new drugs, are paring back research. Promising discoveries in illnesses like depression and Parkinson’s that once would have led to clinical trials are instead going unexplored because companies have neither the will nor the resources to undertake the effort.
The initial financing of the government’s new drug center is relatively small compared with the $45.8 billion that the industry estimates it invested in research in 2009. The cost of bringing a single drug to market can exceed $1 billion, according to some estimates, and drug companies have typically spent twice as much on marketing as on research, a business model that is increasingly suspect.
The National Institutes of Health has traditionally focused on basic research, such as describing the structure of proteins, leaving industry to create drugs using those compounds. But the drug industry’s research productivity has been declining for 15 years, “and it certainly doesn’t show any signs of turning upward,” said Dr. Francis S. Collins, director of the institutes.
The job of the new center, to be called the National Center for Advancing Translational Sciences, is akin to that of a home seller who spruces up properties to attract buyers in a down market. In this case the center will do as much research as it needs to do so that it can attract drug company investment.
That means that in some cases, the center will use one of the institutes’ four new robotic screeners to find chemicals that affect enzymes and might lead to the development of a drug or a cure. In other cases, the center may need to not only discover the right chemicals but also perform animal tests to ensure that they are safe and even start human trials to see if they work. All of that has traditionally been done by drug companies, not the government.
“None of this is intended to be competitive with the private sector,” Dr. Collins said. “The hope would be that any project that reaches the point of commercial appeal would be moved out of the academic support line and into the private sector.”
Whether the government can succeed where private industry has failed is uncertain, officials acknowledge, but they say doing nothing is not an option. The health and human services secretary, Kathleen Sebelius, sent a letter to Congress on Jan. 14 outlining the plan to open the new drug center by October — an unusually rapid turnaround for an idea first released with little fanfare in December.
Creating the center is a signature effort of Dr. Collins, who once directed the agency’s Human Genome Project. Dr. Collins has been predicting for years that gene sequencing will lead to a vast array of new treatments, but years of effort and tens of billions of dollars in financing by drug makers in gene-related research has largely been a bust.
As a result, industry has become far less willing to follow the latest genetic advances with expensive clinical trials. Rather than wait longer, Dr. Collins has decided that the government can start the work itself.
“I am a little frustrated to see how many of the discoveries that do look as though they have therapeutic implications are waiting for the pharmaceutical industry to follow through with them,” he said.
Dr. Collins’s ability to conceive and create such a center in a few short months would have been impossible for most of his predecessors, who had nice offices but little power. But Congress in recent years has invested real budgetary and administrative authority in the director’s office, and Dr. Collins is the first to fully use these new powers.
Under the plan, more than $700 million in research projects already under way at various institutes and centers would be brought together at the new center. But officials hope that the prospect of finding new drugs will lure Congress into increasing the center’s financing well beyond $1 billion.
Hopes of new money may be optimistic. Republicans in the House have promised to cut the kind of discretionary domestic spending that supports the health institutes, and officials are already bracing for significant cuts this year. But Dr. Collins has hinted that he is willing to cannibalize other parts of the health institutes to bring more resources to the new center.

“There are some people that would say this is not the time to do something bold and ambitious because the budget is so tight,” he said. “But we would be irresponsible not to take advantage of scientific opportunity, even if it means tightening in other places.”

Readers' Comments

Readers shared their thoughts on this article.
For the plan to go into effect by October, the administration must by law get rid of one of the 27 centers and institutes already in existence at the N.I.H. — something that has never been done before. So the administration plans to downgrade the National Center for Research Resources, in part by giving some of its functions to the new drug center.
Researchers and staff members connected to the research resources center have inundated a complaint blog about the coming change. Mark O. Lively, a professor of biochemistry at Wake Forest University and a member of an advisory council to the research resources center, said that he could not understand why the administration was moving so quickly with its plans.
“And the N.I.H. is not likely to be very good at drug discovery, so why are they doing this?” Dr. Lively asked.
But Dr. Garret A. FitzGerald, a professor of medicine and pharmacology at the University of Pennsylvania, said the new center could inspire universities to train a new generation of investigators who could straddle the divide between academia and industry.
“It could be a really good idea,” he said.
Both the need for and the risks of this strategy are clear in mental health. There have been only two major drug discoveries in the field in the past century; lithium for the treatment of bipolar disorder in 1949 and Thorazine for the treatment of psychosis in 1950.
Both discoveries were utter strokes of luck, and almost every major psychiatric drug introduced since has resulted from small changes to Thorazine. Scientists still do not know why any of these drugs actually work, and hundreds of genes have been shown to play roles in mental illness — far too many for focused efforts. So many drug makers have dropped out of the field.
For Dr. Thomas R. Insel, director of the National Institute of Mental Health, the drug industry’s departure from this vital research area shows that the government must do something, although he acknowledges the risk.
“Would we be foolish — we being an agency that has never developed drugs and actually doesn’t know how to do therapeutics that well — to get into this space?” Dr. Insel asked.
But Dr. William Potter, who was once a top researcher at the mental health institute and retired last year as the vice president of translational neuroscience at the giant drug maker Merck, said that far more basic research needed to be done on the causes of mental illness before anyone — industry or government — could successfully create breakthrough drugs.
“We still don’t even understand how lithium works,” Dr. Potter said. “So how do people think we can find drugs systematically for mental illness?”


So join me in writing to suggest looking at stroke rehab drugs. With 800,000 strokes a year and the only acute drug available being tPA this area is ripe for research, and the cost/benefit ration could be huge.

Friday, April 8, 2011

Most stroke patients not getting clot-busting treatment in timely manner

This was a rather disturbing article but not for the reason you think, the poor response rate of administering tPA. The main problem with this article is: The assumption that just fixing the delivery of tPA is the way to go. Where are the critcal thinkers and planners that don't have tunnel-vision and only one way of fixing the problem. If you read a lot of my earlier posts you will find numerous therapies that could be used in the acute phase. Where are the researchers that can be recruited to look into these options? There are numerous possibilities of preventing cell death or repairing it more easily.  Where are all the smart forward thinkers about stroke rehab?

http://cpr-professionals.com/blog/?p=290
American Stroke Association Meeting Report Study Highlights:
Researchers say the findings support the need for a targeted national initiative to treat patients more quickly with tPA.
LOS ANGELES, Feb. 10, 2011 ? Less than one-third of acute stroke patients treated with intravenous tissue plasminogen activator (tPA) receive the clot-busting drug within 60 minutes of their hospital arrival, according to research presented at the American Stroke Association’s International Stroke Conference 2011. The research is simultaneously published in Circulation: Journal of the American Heart Association.
The drug is a proven intervention for acute ischemic stroke patients, but can only be given within 4.5 hours after stroke onset and has the greatest benefits when given earlier in that timeframe.
Despite proven benefits, guidelines recommendations and explicit goals for administering tPA in a timely manner, the drug’s administration has not been well studied, said Gregg C. Fonarow, M.D., lead author of the study and professor of cardiovascular medicine at the University of California-Los Angeles.
In abstract 205, Fonarow and colleagues reported the frequency, patient and hospital characteristics, trends and outcomes of ischemic stroke with door-to-needle times of 60 minutes or less.
They analyzed data from 1,082 hospitals from the American Heart Association/American Stroke Association’s Get With The Guidelines®–Stroke quality improvement program between April 2003 and September 2009. Specifically, the researchers looked at 25,504 acute ischemic stroke patients treated with tPA within three hours of symptom onset.
They found during that time, 6,790, or 26.6 percent, received tPA in 60 minutes or less – with only modest improvement over the past 6.5 years – from 19 percent in 2003 to 29 percent in 2009.
Patients who were younger, male, white and had no prior stroke were most likely to receive the therapy within the 60-minute window, Fonarow said.
“It is a concern that older patients, women and black patients were less likely to receive timely tPA administration,” he said. “It’s also notable that the symptom onset-to-arrival times were shorter in patients with door-to-needle times of greater than 60 minutes, suggesting that hospitals were taking a more relaxed approach to the administration of tPA in earlier arriving patients.”
Hospitals that had greater annual volumes of tPA-treated stroke patients were more likely to administer the therapy within 60 minutes of hospital arrival.
“This suggests that greater hospital team experience translates into improved performance,” said Fonarow, immediate-past chair of the Get With The Guidelines Steering Committee.
The proportion of patients with door-to-needle times of 60 minutes or less varied widely by hospital. Some hospitals did not achieve tPA administration within the ideal time frame for any patient. Other hospitals achieved door-to-needle times of 60 minutes or less in 80 percent or more of patients.
In abstract 146, the team also demonstrated that in-hospital mortality was significantly lower among patients treated more timely with tPA, and there were fewer complications with more timely treatment.
“These findings demonstrate for the first time that shorter door-to-needle times improve the likelihood that acute ischemic stroke patients will survive,” Fonarow said.
The study identifies substantial opportunities nationally for improving the speed of tPA therapy initiation in acute ischemic stroke patients, he said.
“These findings suggest there is a critical need for a targeted campaign tailored to increase the portion of patients with door-to-needle times 60 minutes or less, such as the recently launched American Stroke Association Target®: Stroke initiative,” Fonarow said. “Nearly 1,000 hospitals across the country are now registered to use Target: Stroke information and tools to improve their door-to-needle time for administering tPA to appropriate stroke patients.”

The targeted national initiative they talk about should just ask survivors what to do.

Cardiac Glycosides and stroke rehab

At last a therapy that can be used up to six hours after and doesn't need to worry about it being a bleed.
This is just a laboratory model so it has lots of trials and testing to do.


Using a novel screening technology, Duke University Medical Center researchers have shown that drugs called cardiac glycosides can protect brain cells from death after stroke in laboratory models, and that the drugs are effective even if delivered six hours or more after the onset of stroke conditions (1).

“This discovery is exciting because it may lead to interventions to prevent or lessen the amount of brain damage suffered after stroke,” said Donald C. Lo, Ph.D., director of the Center for Drug Discovery and associate professor of neurobiology at Duke, and primary investigator on the study

Currently, only one drug has been approved by the Food and Drug Administration to treat stroke — and it faces serious limitations, Lo said. Called recombinant tissue plasminogen activator, the drug must be given within a three-hour window after the onset of stroke. Also, because the drug is delivered intravenously and acts by breaking blood clots, it is ineffective against “hemorrhagic” strokes that happen when an artery bursts.

Lo speculates that cardiac glycosides may exert their beneficial effect during stroke in an analogous manner that in heart disease, by restoring calcium to healthy levels in brain cells and thereby preventing cell death. Calcium plays a key role in regulating normal cell function, and any changes in its cellular concentration — such as those caused by stroke — can be toxic (2).

Another recent study with statin drugs concluded that its use is associated with a reduced risk of stroke but not severity or mortality (3)

Related to the Duke University Medical Center research, a case study from Brazil confirm the very low mortality for stroke in 1150 patients with stable heart disease taking cardiac glycosides, during 28 years. The study was authored by Quintiliano H. de Mesquita and Claudio A. S. Baptista and published in Ars Cvrandi, a Brazilian medical journal in 2002 (4)

The stroke (ischemic + hemorrhagic) mortality in 28 years for the cardiac patients taking cardiac glycosides was:

994 patients w/out prior infarction – Stroke mortality: 13 cases (1.3%) = 0.04% per year.
156 patients with prior infarction – Stroke mortality: 7 cases (4.4%) = 0.15% per year.
For a better comparison in stroke mortality, with those taking cardiac glycosides, we can take the data from the HPS study, which had a follow-up of 5 years, involving 20.536 patients aged 40-80 years with coronary heart disease, other vascular diseases or diabetes. The HPS found a total stroke mortality of 0.9% (0.18% per year) in patients taking statins and 1.2% (0.24% per year) in patients taking placebo (5)

The permanent use of cardiac glycosides (Digitoxin, Digoxin, Acetildigoxin, Lanatoside-C, Betametildigoxin, or Proscillaridin-A) in low, daily therapeutic (non-toxic) doses from the Brazilian study was based on the Myogenic Theory of Myocardial Infarction and had as its objective the prevention of acute coronary syndromes (6, 7). The global mortality for the patients without previous myocardial infarction was 14.2% (0.5% per year), while the global mortality for the patients with previous myocardial infarction was 41.0% (1.4% per year). The numbers for mortality and morbidity are described in the Table 5 of the article. (1)

References

1.    Cardiac glycosides provide neuroprotection agains ischemic stroke: Discovery by a brain slice-based compound screening platform, James K. T. Wang, Donald C. Lo et al, Proc Natl Acad Sci U S A. 2006 Jun 22; Full and free text at http://www.pubmedcentral.gov/picrender.fcgi?artid=1481664&blobtype=pdf

2.    Study Spots Potential Stroke Drugs, http://www.dukemednews.org/news/article.php?id=9754

3.    Statin use and sex-specific stroke outcomes in patients with vascular disease, Cheryl D. Bushnell et al, Stroke, 2006; 37:1427

4.    Cardiotonico: Insuperavel na Preservacao da Estabilidade Miocardica como Preventivo das Sindromes Coronarias Agudas e Responsavel pela Prolongada Sobrevida–Casuistica de 28 anos (1972-2000), Mesquita, QHde e Baptista, CAS. Ars Cvrandi. May 2005, Volume 35, republished in 2005 at http://www.infarctcombat.org/28anos/digitalicos.html, with summary in English at http://www.infarctcombat.org/heartnews-16.html.

5.    The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomized placebo-controlled trial, Heart Protection Study Collaborative Group. BMC Medicine 2005, 3:6 — http://www.biomedcentral.com/1741-7015/3/6

6.    Myogenic Theory of Myocardial Infarction Book with summary in English at http://www.infarctcombat.org/LivroTM/parte8.htm.

7.    Some articles in English about the Myogenic Theory are available at: http://www.infarctcombat.org/MyogenicTheory.html.


So who is going to drive this to testing trials?

Therapist homework

I know this is really arrogant but we need to give some homework to our therapists. We should be able to get a detailed breakdown of muscle movement detailing each muscle that needs to move or relax and then correlate that to our movements. For example - Walking; for each phase of walking there should be a stipulation of what needs to occur; ie. fire this muscle, relax this muscle. Instead right now we get; walk this way. The therapists are assuming that we still have pre-motor control which does the coordination. Then we could use those details to set up exercises and eventually put these separate movements together to get smooth movements again. This should be available already from when therapists were in school.
This comment from a therapist;
'I started seeing him last week and has no movement at all on LEFT arm.I read that no shoulder shrug or finger movements are not good prognosis.'
is rather telling because it makes the assumption that the only stuff that is possible to recover is in the penumbra from a clot or the bleed drainage area from a bleed. In other words only those areas that were partially damaged. With this false assumption you will never get therapy that might bring back functions neuroplastically into new locations.

Ok two assignments;
1. describe in detail each voluntary muscle used in walking for each phase of swing, both which ones are actively used and which ones need to relax. Describe/draw exercises for each muscle, including the ones that need to relax. This should be common for all people. What may be different is the deficits that each person has.
2. Create therapies for the scenario above where no movement exists in the arm, including research proof that they are valid.

Please no excuses that 'All strokes are different, all stroke recoveries are different'.

Thursday, April 7, 2011

tactile devices for stroke rehab

Finally, someone who gets  the idea that maybe sensation may help motor control.
http://www.news-medical.net/news/20110405/Tactile-devices-generate-realistic-sense-of-touch-and-sensation-for-stroke-victims.aspx
Devices which could be used to rehabilitate the arms and hands of people who have experienced a stroke have been developed by researchers at the University of Southampton.
In a paper to be presented this week (6 April) at the Institution of Engineering and Technology (IET) Assisted Living Conference, Dr Geoff Merrett from ECS-Electronics and Computer Science, will describe the design and evaluation of three technologies which could help people who are affected by stroke to regain movement in their hand and arm.
Dr Merrett worked with Dr Sara Demain from the University's Faculty of Health Sciences and Dr Cheryl Metcalf who works across Health Sciences and ECS, to develop three 'tactile' devices which generate a realistic "sense of touch" and sensation which mimic those involved in everyday activities.
"Most stroke rehabilitation systems ignore the role of sensation and they only allow people repetitive movement," said Dr Demain. "Our aim is to develop technology which provides people with a sense of holding something or of feeling something, like, for example, holding a hot cup of tea, and we want to integrate this with improving motor function."
Three tactile devices were developed and tested on patients who had had a stroke and on healthy participants. The devices were: a 'vibration' tactile device, which users felt provided a good indication of touch but did not really feel as if they were holding anything; a 'motor-driven squeezer' device, which users said felt like they were holding something, a bit like catching a ball; and a 'shape memory alloy' device which has thermal properties and creates a sensation like picking up a cup of tea.
"We now have a number of technologies, which we can use to develop sensation," said Dr Merrett.
"This technology can be used on its own as a stand-alone system to help with sensory rehabilitation or it could be used alongside existing health technologies such as rehabilitation robots or gaming technologies which help patient rehabilitation," Dr Metcalf concluded.
The academics' paper: Design and Qualitative Evaluation of Tactile Devices for Stroke Rehabilitation will be presented at the Institution of Engineering and Technology (IET) Assisted Living Conference.
More information: The academics' paper: Design and Qualitative Evaluation of Tactile Devices for Stroke Rehabilitation will be presented at the Institution of Engineering and Technology (IET) Assisted Living Conference. A copy of the paper can be accessed at: http://eprints.ecs.soton.ac.uk/.

Here is the full paper
http://eprints.ecs.soton.ac.uk/21802/1/merrett.pdf
It contains some pictures of what these look like.
This idea is referred to in this book.
Sensory re-education of the hand after stroke by Yekeutiel, Margaret published in 2000. God it only took 11 years to translate to practice.

Influence stroke rehab

Trying to influence better stroke rehabilitation knowledge dissemination is extremely hard. I'm going to suggest we start at the top; The World Stroke Organization. If you look at their website there is nothing for survivors, we are just the fodder to present as pitiable objects that will lead to additional funding for them to use.
I asked them in an email once where were the rehab protocols and they just dismissively told me to contact the American Stroke Association or the National Stroke Association of the US. What a copout, they already knew that these two organizations don't have protocols and don't care about survivors. Their address and email are here:
WSO Administrative Office
c/o Kenes International
1-3, rue de Chantepoulet
P.O. Box 1726, CH-1211 Geneva 1
Switzerland
Tel: + 41 22 906 9166
Fax: +41 22 906 26 07
E-mail: admin@world-stroke.org

They also have a journal, this is where you go to get rules on how to submit an article to them. Please consider writing up your concerns and submitting them as an opinion article.
http://mc.manuscriptcentral.com/ijs
As you can see from the description they don't care about survivors;
The International Journal of Stroke is a clinically-oriented, truly global, stroke journal.
I wrote up one on the future of stroke rehab as seen by a survivor. It was rejected but at least the reviewers had to read and discuss the pathetic nature of stroke research.

Try asking for stroke protocols for dead brain function rehabilitation or what is happening with neurogenesis, neuroplasticity.
I know this is tilting at windmills but if we could get millions to deluge them, they might actually consider doing something for survivors. I did read once that there were 63 million survivors in the world. Pass this on, we have to start somewhere. Eventually we can work on our national stroke associations, maybe bottom up might work better but top-down dictators are usually faster. Democracy takes a long time to implement. This directly relates to my posting on stroke rehab vs. world domination.
http://oc1dean.blogspot.com/2010/11/world-domination-vs-stroke-rehab.html

When you do this do not mention anything specific about your condition/problems, that will be used to dismiss you because it will be seen as asking for medical advice. The National Stroke Association used this comment to me once when I was just trying to find out what therapies were used for spasticity;
'this question falls under our organizational guidelines as a medical inquiry and we defer to the medical community to respond.' The medical community has already responded; 'I know nothing'. You are on your own, good luck and good-bye.
If you don't want to start there, if you are in the US you can write to the president, I did.
http://oc1dean.blogspot.com/2010/09/letter-to-president.html

Wednesday, April 6, 2011

stiff arteries - risk of stroke

I didn't see any actual measurements in the article but the video made it look like maybe reaching your toes was ok.
http://www.associatedcontent.com/article/7708234/do_this_test_to_find_out_if_you_have.html

So I tried this, getting down to the floor was interesting. With my good arm I was able to touch my toes, with my bad arm I guess I am at extreme risk for another stroke or heart attack.

A simple test that measures trunk flexibility could say a lot about your risk of dying of a heart attack or stroke. According to a study published in the American Journal of Physiology, poor trunk flexibility is aAdChoices

marker for arterial stiffness, a condition that increases the risk of deadly heart disease and strokes.
Trunk Flexibility and Arterial Stiffness: How Far Can You Reach?
Researchers used the sit-and-reach test to measure the trunk flexibility of 526 healthy adults. The participants were asked to sit on the floor with their legs straight and their backs pressed against a wall. Then they were asked to bend forward while the researchers measured how far they could reach with their hands. They also measured their blood pressure and did other tests to assess their degree of arterial stiffness. What did they find?
In those over 40, lack of trunk flexibility was a good marker for stiff arteries in this group. Older adults who had limited trunk flexibility and an inability to reach very far when sitting had a greater degree of arterial stiffness. Older adults with poor trunk flexibility also had higher systolic blood pressures, on average.
Yoga and Pilates: Good for More than Your Abdominals?
Now, researchers have another question. Will a program designed to increase trunk flexibility reduce arterial stiffness and the risk of heart disease? One of the authors of the study, Kenta Yomamoto, is hopeful.
He and his colleagues believe that stretching the muscles in the trunk and increasing the flexibility of these muscles helps to "relax" stiff arteries and reduce blood pressure. They speculate that exercise programs that focus on flexibility such as yoga and Pilates could help to reduce arterial stiffness, and, possibly, the risk of heart disease and stroke.

Tuesday, April 5, 2011

statins and stroke survival

I guess statins are being pushed for everything.
http://www.medwire-news.md/39/91658/Stroke/Acute_statin_therapy_improves_survival_after_ischemic_stroke.html
MedWire News: Prestroke and acute poststroke statin therapy can significantly improve survival rates in ischemic stroke patients, show study results.
Danielle Ní Chróinín (Mater University Hospital, Dublin, Ireland) and colleagues investigated whether statin therapy at or before stroke onset improved early and late outcomes in 448 ischemic stroke patients (aged =18 years) from the North Dublin Population Stroke Study.
Prestroke and acute (=72 hours) poststroke medications were recorded for all patients, and follow-up assessments were performed at 7, 28, and 90 days, and after 1 year.
Overall, the researchers found that statins were prescribed before stroke onset in 30.1% of patients and was continued after stroke in 87.3% of these patients. An additional 42.5% of patients were given statin therapy within 72 hours of stroke onset.
After adjusting for age, prestroke disability, National Institutes of Health Stroke Scale (NIHSS) score, hypertension, and aspirin use, patients treated acutely with statins poststroke were 88% more likely to survive to 7 days than untreated patients, and 81% and 74% more likely to survive to 90 days and 1 year, respectively.
Similar findings were observed in the group prescribed statins before stroke onset; treatment was associated with a 96% improvement in 7-day survival, and a 77% and 52% improvement in 90-day and 1-year survival, respectively, compared with untreated patients.
In addition, acute statin treatment after stroke was associated with a 2.23- and 2.20-fold improvement in functional outcomes at 7 days and 90 days, respectively, compared with no treatment, while prestroke therapy was associated with a respective 1.68- and 1.80-fold improvement.
"The potential effects of acute statin treatment after stroke are particularly relevant," comment Chróinín et al in the journal Stroke.
"Most patients experiencing stroke will not be using statin therapy before stroke onset, and clinical trials of acute statin therapy would likely begin treatment in this time window to maximize anticipated benefits," they explain.
MedWire (http://www.medwire-news.md/) is an independent clinical news service provided by Springer Healthcare Limited. © Springer Healthcare Ltd; 2011

Or maybe this is just a result of being told you are taking statins to improve your helth and keep you alive. Placebo effect again
I thought about this incorrectly, I thought this was for rehab but it actually is just for survival.

dead brain look

I heard about this from a therapist once. An arm that bounces into your leg as you walk. In my case if I am using my cane it hits my leg, without my cane the arm bangs into my crotch. Lovely situation for a guy.

arm-hand stroke exercises by madfit

Madfit has posted these on several stroke forums. They are so good they need to be distributed again. You won't get something like this from your therapist so since this is a non-medical source it is not worth listening to.
http://www.stroke-survivors.co.uk/forum/viewpostsbyuser.aspx?UserID=106

When you read these you can see that she covers the therapy needed for those muscles that still partially work, and goes to passive movement to neuroplastically get functions that were in the dead area moving again. She also worked on sensations which has been proven to help movement.

Here are the exercises:
1. Take your arm, and with the other hand massage the affected arm, trying to loosen the muscles. If you keep doing this, eventually it will loosen up. In rehab this method is called Miofacial Release. The therapist did for me and I continued to do it at home. It really worked on me. Ask at Rehab if they offer it.
2. Stengthen your whole arm including your fingers, by taking a plastic grocery bag and put a few groceries, adding more and more weight when you think you can. You'll be surprised, by carrying the bag with 2 or 3 fingers, you'll see how strong both the fingers and arm become and the muscles will loosen up.
3. With the affected hand, pull the fingers on the opposite hand, one at a time, and keep stretching them out. Stretch each joint on the finger, the 3 joints on every finger. I constantly did this. My hand used to be like a claw. You should see it now. I am even touch typing this note using every finger on both hands. It takes a strong will, perseverance and a lot of work.
Take the good hand and pull on the thumb stetching it, farther and farther from the index finger. After a while, you'll notice you can separate the thumb from the index finger until it is normal like your good hand.
4. Then when you have accomplished this, just try opening and closing the fingers, over and over until they become strong.
5. Use a tight springed clothes pin, and keep pressing it open, this will also give strength to the fingers.
6. Put some small type shaped pasta or marbles in a bowl and try picking one at a time up. This gives coordination.
7. Did they give you puddy in therapy? That was also good to build strength.
8. It's very important to do exercises all the time. Just relaxing in bed, sitting in a chair or anyplace. I even used to do this when someone took me by car shopping, after a while it will be instinctive. I can personally attest to these exercises helping.
9. Use the squeeze ball method to gain strength, while watching TV, in a car, etc.
Now I touch-type, that is using both hands and all fingers, I do everything with the affected hand. The only thing I cannot do well is write. The precise coordination which is needed in the wrist I still don't have for writing. It takes alot of hard work, a strong will, and dedication every day, as well as prayers. But it does work.
I had a pretty bad stroke in October 2002, when I was 55 years old with a good job. I was totally paralyzed on my right side (leg and arm). I had about 3 months in-patient therapy, and 2 months outpatient therapy. Eventually went home in a wheelchair.
I was told I probably would walk eventually with a cane, but several doctors told me I would never have function of my right arm and hand. I told them I don't accept their prognosis. I might add that I am a right-handed person, so that made it even worse. I had to learn to write and do things with my left hand.
Hope this helps you! Good luck.

sonar stroke detector

Reminds me of the phrenology craze of 1810 to 1840; http://en.wikipedia.org/wiki/Phrenology
http://www.ideaconnection.com/new-inventions/sonar-stroke-dectector-04508.html
But if it works we could get tPA to appropriate subjects faster. And you might not need a neurologist on site to read the MRI findings.

prolonged muscle stretch on spastic muscle of stroke patients

A little bit more of news on the spasticity front. Ask your therapist if this might help you. This is only 10 years old so if your therapist doesn't know this ask them why.
http://www.ncbi.nlm.nih.gov/pubmed/11370763
Department of Industrial Management, Southern Taiwan University of Technology, Tainan, ROC.
by KH Tsai - 2001

Abstract

The control of spasticity is often a significant problem in the management of patients with spasticity. The aim of this study was to evaluate the effect of a single session of prolonged muscle stretch (PMS) on the spastic muscle. Seventeen patients with spastic hemiplegia were selected to receive treatment. Subjects underwent PMS of the triceps surae (TS) by standing with the feet dorsiflexed on a tilt-table for 30 minutes. Our test battery consisted of four measurements including the modified Ashworth scale of the TS, the passive range of motion (ROM) of ankle dorsiflexion, the H/M ratio of the TS, and the F/M ratio of the tibialis anterior (TA). The results indicated that the passive ROM of ankle dorsiflexion increased significantly (p < 0.05) compared to that before PMS treatment. Additionally, PMS reduced motor neuron excitability of the TS and significantly increased that of the TA (p < 0.05). These results suggest that 30 minutes of PMS is effective in reducing motor neuron excitability of the TS in spastic hemiplegia, thus providing a safe and economical method for treating stroke patients.

I do wish they had come up with another acronym, I really don't want to say I worked on PMS with my therapist today. Most of my therapists were women,  I can just hear them saying, ' We're going to work on your PMS today'.